Asad Haider
Stock Analyst at Goldman Sachs
(2.39)
# 2,303
Out of 4,918 analysts
7
Total ratings
100%
Success rate
8.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Initiates: Neutral | $27 | $21.28 | +26.88% | 1 | Jul 17, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $107.34 | +2.48% | 1 | May 29, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $167.33 | +2.79% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $762.33 | +16.48% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $195.22 | -0.62% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $44.23 | +24.35% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $23.49 | +6.43% | 1 | Apr 8, 2025 |
NewAmsterdam Pharma Company
Jul 17, 2025
Initiates: Neutral
Price Target: $27
Current: $21.28
Upside: +26.88%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $107.34
Upside: +2.48%
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $167.33
Upside: +2.79%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $762.33
Upside: +16.48%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $195.22
Upside: -0.62%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $44.23
Upside: +24.35%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $23.49
Upside: +6.43%